PharmaMar
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, PharmaMar sits in the top decile of US sponsors by registered trial count (#513 of 15,742 sponsors by registered trial count).
PharmaMar: 32 sponsored US clinical trials, 4 recruiting.
PharmaMar sponsors 32 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting, and 20 completed. 5 of these trials are in Phase 3-4 (later-stage) and 27 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Solid Tumors, with 2 trials.
Top-decile sponsor footprint
PharmaMar ranks in the top decile of sponsors by registered trial count (#513 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
20 of 27 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (74.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
32 total, page 1 of 1
Study of PM54 in Combination With Immunotherapy in Adult Participants With Advanced Malignancies
NCT07644039
Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)
NCT06088290
Clinical Trial of PM54 in Advanced Solid Tumors Patients.
NCT05841563
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
NCT05076396
Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)
NCT05153239
Clinical Trial of PM60184 in Advanced Colorectal Cancer After Standard Treatment
NCT03427268
A Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma
NCT03070964
Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer
NCT02566993
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
NCT02611024
Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors
NCT02454972
Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization in Patients With Selected Solid Tumors
NCT02451007
Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients
NCT02421588
Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM060184 in Combination With Gemcitabine in Selected Patients With Advanced Solid Tumors
NCT02533674
A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients
NCT01951157
Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors
NCT01831089
A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer
NCT01525589
Study of PM01183 in Non-Colorectal Cancer Patients as a Days 1 and 8 Intravenous Short Infusion Every 3 Weeks
NCT01405391
Clinical Study of PM01183 in Patients With Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome
NCT01314599
Study of PM060184 in Patients With Advanced Solid Tumors
NCT01299636
Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy
NCT01222767
Clinical Trial of Aplidin® in Patients With Primary Myelofibrosis
NCT01149681
Aplidin - Dexamethasone in Relapsed/Refractory Myeloma
NCT01102426
Clinical Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy
NCT00900562
Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM01183 in Patients With Advanced Solid Tumors
NCT00877474
Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors
NCT00884845
Study of Plitidepsin in Combination With Sorafenib or Gemcitabine in Patients With Advanced Solid Tumors or Lymphomas
NCT00788099
Clinical Study of Plitidepsin (Aplidin®) in Combination With Cytarabine in Patients With Relapsed/Refractory Leukemia
NCT00780143
A Phase I Study of Zalypsis (PM00104) in Subjects With Advanced Malignant Solid Tumors or Lymphoma
NCT00359294
A Phase I Study of PM02734 in Subjects With Advanced Malignant Solid Tumors
NCT00404521
A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma
NCT00229203
A Study of Aplidin ( Plitidepsin) in Subjects With Advanced Prostate Cancer
NCT00780975
Ecteinascidin 743 in Treating Patients With Malignant Mesothelioma
NCT00027508
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 15 |
| Phase 2 | 12 |
| Phase 3 | 5 |
What is open in the PharmaMar pipeline
4 recruiting of 32 indexed (13% open); 20 completed (63%).
Phase mix: 5 late (III/IV) vs 27 early (I/II) (early-phase heavy).
Top condition: Advanced Solid Tumors (2 trials), 6 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
PharmaMar: open-pipeline peers nationwide
Peers matched on 32 registered trials and 13% open enrollment, not the therapeutic-area sidebar.
PharmaMar sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 32 trials (± recruiting share)
- Aerie Pharmaceuticals · 32 trials · 0% recruiting
- Allina Health System · 32 trials · 3% recruiting
- Ardea Biosciences · 32 trials · 0% recruiting
- Hebrew SeniorLife · 32 trials · 19% recruiting
Sponsors near 13% open enrollment (± trial volume)
- Addario Lung Cancer Medical Institute · 13% recruiting · 8 trials
- American University · 13% recruiting · 16 trials
- Annexon · 13% recruiting · 8 trials
- Ansun Biopharma · 13% recruiting · 8 trials
Related
What to do with this PharmaMar page
32 registered trials is a research-attention snapshot, not an endorsement of PharmaMar or any single study.
- 4 of PharmaMar's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Advanced Solid Tumors is the condition PharmaMar studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Advanced Solid Tumors trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
PharmaMar pipeline card: 32 registered trials from official public datasets.Report a data error.